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Abstract
Introduction: Single nucleotide polymorphisms (SNPs) in approximately 40 genes have been associated with an increased
risk for type 2 diabetes (T2D) in genome-wide association studies. It is not known whether a similar genetic impact on the
risk of prediabetes (impaired glucose tolerance [IGT] or impaired fasting glycemia [IFG]) exists.
Methods: In our cohort of 1442 non-diabetic subjects of European origin (normal glucose tolerance [NGT] n=1046, isolated
IFG n=142, isolated IGT n=140, IFG+IGT n=114), an impact on glucose homeostasis has been shown for 9 SNPs in previous
studies in this specific cohort. We analyzed these SNPs (within or in the vicinity of the genes TCF7L2, KCNJ11, HHEX, SLC30A8,
WFS1, KCNQ1, MTNR1B, FTO, PPARG) for association with prediabetes.
Results: The genetic risk load was significantly associated with the risk for IGT (p=0.0006) in a model including gender, age,
BMI and insulin sensitivity. To further evaluate potential confounding effects, we stratified the population on gender, BMI
and insulin sensitivity. The association of the risk score with IGT was present in female participants (p=0.008), but not in
male participants. The risk score was significantly associated with IGT (p=0.008) in subjects with a body mass index higher
than 30 kg/m
2 but not in non-obese individuals. Furthermore, only in insulin resistant subjects a significant association
between the genetic load and the risk for IGT (p=0.01) was found.
Discussion: We found that T2D genetic risk alleles cause an increased risk for IGT. This effect was not present in male, lean
and insulin sensitive subjects, suggesting a protective role of beneficial environmental factors on the genetic risk.
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Introduction
The etiology of type 2 diabetes (T2D) is multifactorial, because
it arises from a complex interaction between environmental factors
and genetic susceptibility [1]. The major environmental causes are
sedentary lifestyle and high energy intake leading to obesity and
insulin resistance. Genetic susceptibility is determined by a
multitude of genes contributing to the overall predisposition, each
gene having a rather small individual effect [2,3]. Most of the
approximately 40 known genetic variants conferring increased risk
for T2D have been discovered by genome-wide association studies
(GWAS) [4]. With this method, associations between genomic
variants and diabetes prevalence or quantitative glycemic traits
like increased fasting plasma glucose or 2-hour plasma glucose can
be established [5]. Most discovered diabetes-risk variants have a
predominant effect on insulin secretion, and there are only few
that markedly influence body adiposity and insulin sensitivity [2].
The natural history of type 2 diabetes (T2D) includes
hyperglycemic states preceding the manifestation of overt diabetes
[6,7]. Only 50% of individuals with IGT progress to diabetes over
their lifetime and the annual progression rate vary from 2.3 to
11% [8]. Impaired glucose tolerance (IGT) is independently
associated with an elevated risk for atherosclerotic vascular
diseases [9–11].It has been shown that summation of known
diabetes-risk alleles increases the incidence of T2D [12,13].
However, it is unknown whether previously identified diabetes
risk genes can also determine risk for prediabetes. Several genetic
variants have been identified in GWAS which associate with
fasting glucose or postload glucose after OGTT. To our
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tested in association with a genetic risk score. We therefore aimed
to answer the question whether known genetic variants bearing
susceptibility for diabetes can also determine risk for prediabetes
(IFG or IGT). We investigated 9 single nucleotide polymorphisms
(SNPs) which were previously shown to associate either with
insulin sensitivity or with insulin secretion in our study population.
The examined SNPs were rs7903146 in TCF7L2, rs7923837 in
HHEX, rs13266634 in SLC30A8, rs1001013 in WFS1, rs5219 in
KCNJ11, rs151290 in KCNQ1, rs10830963 in MTNR1B,
rs8050136 in FTO and rs1808282 in PPARG, as genotyped for
previous investigations [14–20]. Seven of these SNPs primarily
modulate insulin secretion (TCF7L2, HHEX, SLC30A8, WFS1,
KCNJ11, KCNQ1, MTNR1B).
Methods
Subjects
We studied 1442 non-diabetic persons with European ancestry
who were selected from the on-going TUEbingen Family study
(TUEF). Data of this study population have been used in previous
publications [14–20], but a genetic risk score was not tested for
prediabetes as outcome parameter in this population before. Up to
now, more than 2000 individuals who are at increased risk of T2D
have participated in the study. Increased risk of diabetes was
defined as family history of type 2 diabetes, BMI .27 kg/m
2 or
prior diagnosis of IGT. Most of the participants were recruited by
newspaper advertisements. Participants were first interviewed on
telephone. Those who fulfilled the inclusion criteria were invited to
visit the test facility of the university hospital. Informed written
consent was obtained from all participants and the Ethics
Committee of the medical faculty of the University of Tu ¨bingen
approved the protocol. Anthropometric parameters and blood
pressure were measured. A 12-lead ECG test was performed. A
physician obtained detailed medical history and performed a
physical examination. Persons with symptomatic cardiovascular or
endocrine disease, abnormal ECG or serious chronic disease,
judged at the discretion of the attending physician, were excluded
from the study. After excluding participants who turned out to
have diabetes, selection was done based on the availability of the
investigated demographic parameters and genotype data. A
positive family history of diabetes was ascertained if at least one
first-degree relative had diabetes. From 1442 individuals, 34 took
lipid lowering medications (2%) and 114 took antihypertensive
medications (8%).
Obesity was defined as a BMI greater than or equal to 30 kg/
m
2. Information on baseline demographic and glycemic param-
eters of the cohort is provided in Table 1. The insulin resistant and
insulin sensitive subgroups were defined by separating the groups
by the median insulin sensitivity index.
Genotyping
DNA from whole blood was isolated using a commercial DNA
isolation kit (NucleoSpin, Macherey& Nagel, Du ¨ren, Germany).
Genotyping was performed as previously reported [15] [14][16]
using the TaqMan assay (Applied Biosystems, Forster City, CA,
USA). The TaqMan genotyping reaction was amplified on a
GeneAmp PCR System 7000, and fluorescence was detected on
an ABI Prism 7000 sequence detector (Applied Biosystems). The
genotypes were verified in 50 randomly selected subjects by
bidirectional sequencing, and both methods resulted in 100%
identical results. All SNPs obeyed the Hardy-Weinberg equilib-
rium.
Classification of Glycemic Conditions and Calculations
Oral glucose tolerance tests (OGTT) were performed as
recommended by the World Health Organization [21]. Subjects
were classified upon fasting and postload (2-hours) glucose levels
during OGTT according to recommendations of the American
Diabetes Association. Elevated postload glucose (.=7.8 mmol/l)
with normal fasting glucose (,5.6 mmol/l) is termed isolated IGT
(n=140), and elevated fasting glucose (.=5.6 mmol/l) with
normal postload glucose (,7.8 mmol/l) is termed isolated IFG
(n=142) in this study. Because of the pivotal role of postload
hyperglycemia in the development of diabetes [6], the subgroup
termed IGT in this study comprises all participants with elevated
postload glucose (independently of fasting glycemia) (n=254). The
prediabetes subgroup comprises all participants with IFG and/or
IGT (n=396).
For the estimation of insulin sensitivity, the insulin sensitivity
index (ISI) was calculated from glucose and insulin values
throughout the OGTT as proposed by Matsuda and DeFronzo
[22] with the following equation (g denotes glucose, i denotes
insulin levels at specific OGTT time-points):
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Risk Scores
Each SNP was coded as the number of diabetes risk alleles from
0 to 2. Summation of the amount of risk alleles yielded a simple
risk score. The simple (unweighted) risk score r’j (for the
participant j) was calculated as follows:
r0
j ~
X n
i~1
ai,j
We additionally calculated a weighted risk score with a method
described earlier by others [23,24]. In short, the number of per-
SNP risk alleles was multiplied by the SNP-specific effect size.
Effect size was derived from estimated odds ratios of incident
diabetes as found in the literature (see Electronic Table S1). The
risk score rj (weighted risk score for the participant j) was
calculated as follows
rj ~
n
Pn
i~1 bi
X n
i~1
ai,jbi
Where
n is the total number of SNPs investigated, in this case 9, and
ai,j is the risk allele count for SNPi, participant j
bi is the effect size for SNPi which has been calculated as
bi : ~InORithe per allele odds ratio (OR) of SNPi for diabetes
as found in the literature (see Table S1).
Note that n Pn
i~1 bi
is a constant in this study. Its sole function is to
make the weighted risk score easier to interpret, because it is then
comparable with the total number of risk alleles (with the simple
risk score).
Another risk score that mainly reflects disruption of insulin
secretion was constructed from 7 SNPs after omitting the FTO and
PPARG loci.
Genetic Risk Score Predicts Prediabetes
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38224Statistical Analysis
Data are given as means 6 SD when not stated otherwise.
Means were compared with Student’s t test for normally
distributed variables and with the Wilcoxon test for non-normally
distributed variables. Differences between binary outcomes were
tested with Fisher’s exact test. Logistic regression was applied in
the analyses of the multivariable models with the genetic risk score.
Prediabetes categories were used as dichotomous outcomes in
these models. Non-normally distributed variables were trans-
formed to their natural logarithms to approximate normal
distribution; p values were obtained from effect likelihood ratio
tests. Since there was only one statistical hypothesis to test, and all
SNPs included in the risk score were known diabetes SNPs, no
correction for multiple testing was necessary. All tests were
performed as two-tailed tests, a p,0.05 was considered statistically
significant.
Given the distribution of the weighted genetic risk score in
the investigated population, our study had sufficient power (1-
b=0.8) to demonstrate a per-allele odds ratio as low as 1.043
for the whole cohort (n=1440) and an odds ratio of 1.075 for
the smallest subgroup studied (n=456). In order to detect risk
score differences with sufficient power (1-b=0.8), the required
effect sizes for the subgroups prediabetes, IGT, isolated IGT
and isolated IFG were 0.17, 0.19, 0.25 and 0.25, respectively.
All calculations were done with JMP 8.0 (SAS Institute, Cary,
NC, USA), except for sensitivity analyses that were conducted with
G*Power Version 3.1.2 [25].
Results
Seeking to answer the question whether T2D-related genetic
risk determines risk for IGT or prediabetes, we summed up
weighted risk alleles from 9 established diabetes-risk SNPs for each
of the 1442 non-diabetic subjects, and ascertained the clinical at-
risk status from an OGTT according to recommendations of
the ADA.
The weighted genetic risk score was not associated with fasting
glucose after adjustment for gender, age and BMI (p=0.89).
However, it was associated with postload glucose after adjustment
for gender, age and BMI (p=0.002). In logistic regression models
including gender, age, BMI and insulin sensitivity, both the simple
(p=0.014) and the weighted sum of risk alleles (p=0.0006)
predicted the presence of IGT. In the model with the weighted
genetic risk score, gender did not associate with IGT (b=20.195
(0=female, 1=male), p=0.26), but age (b=1.683, p,0.001),
BMI (b=21.337, p=0.001) and insulin sensitivity (b=21.85,
p,0.01) were significant predictors. In an extended model,
variables of lipid metabolism, family history of diabetes and use
of lipid lowering and antihypertensive drugs were added as
covariates. Since LDL and total cholesterol were highly correlated,
adjustment was carried out for LDL, HDL and triglycerides, but
total cholesterol was not included. In this comprehensive model,
the weighted genetic risk score associated with IGT (b=0.15,
p=0.0003) after adjustment for gender, age, BMI, insulin
sensitivity, LDL, HDL, triglycerides, use of lipid lowering drugs,
use of antihypertensives and family history of diabetes.
Table 1. Characteristics of the study population.
female male p NGT
a IFG
b
p
c IGT
d
p
c IFG+IGT
e
p
c
959 483 1046 142 140 114
age (years) 39.2612.9 40.2613.4 0.26 37.5612.4 43.4613.0 ,0.0001 42.1613.2 ,0.0001 49.7613.3 ,0.0001
BMI (kg/m2) 28.768.1 28.167.3 0.66 27.266.8 32.7610.8 ,0.0001 29.767.3 ,0.0001 33.869.6 ,0.0001
family history of diabetes 48.5% 49.0% 0.77 45.8% 58.5% 0.006 60.4% 0.002 52.7% 0.19
systolic blood pressure (mmHg) 121617 126616 ,0.0001 119615 128616 ,0.0001 128616 ,0.0001 134.0618.9 ,0.0001
diastolic blood pressure (mmHg) 75611 77611 0.07 74610 78611 0.002 79612 ,0.0001 81.6610.5 ,0.0001
Fasting glucose (mmol/l) 5.160.5 5.260.6 0.001 4.960.4 5.960.3 ,0.0001 5.160.3 ,0.0001 6.160.3 ,0.0001
2-hour glucose (mmol/l) 6.461.6 6.161.7 0.001 5.661.1 6.261.0 ,0.0001 8.760.8 ,0.0001 9.261.0 ,0.0001
Fasting insulin (pmol/l) 64654 58647 0.005 54643 83672 ,0.0001 71652 ,0.0001 102.4664.0 ,0.0001
2-hour insulin (pmol/l) 4536463 3766412 ,0.0001 3306299 4246345 ,0.0001 7456580 ,0.0001 9286835 ,0.0001
HOMA-ß (AU) 1396139 117686 0.001 1316134 1176104 0.015 1516103 0.004 133676 0.20
HOMA-IR (AU) 2.562.2 2.362.1 0.001 2.061.6 3.663.2 ,0.0001 2.762.0 ,0.0001 4.663.1 ,0.0001
TG (mmol/l) 1.260.8 1.962.8 ,0.0001 1.361.7 1.561.7 0.004 1.862.1 ,0.0001 1.861.4 ,0.0001
Cholesterin (mmol/l) 5.060.9 5.061.1 0.45 5.061.0 5.060.9 0.89 5.261.0 0.022 5.160.9 0.044
HDL (mmol/l) 1.560.4 1.260.3 ,0.0001 1.460.4 1.360.3 0.001 1.460.3 0.008 1.360.3 0.001
LDL (mmol/l) 3.060.8 3.260.8 0.0003 3.060.8 3.160.8 0.24 3.260.8 0.006 3.260.8 0.020
lipid lowering therapy 4.3% 2.4% 0.0007 1.1% 4.9% 0.003 5.7% 0.001 7.0% 0.0002
antihypertensive therapy 9.5% 7.9% 0.12 4.8% 12.7% 0.0007 10.7% 0.009 27.2% ,0.0001
Data are means 6 standard deviations.
anormal glucose tolerance.
bisolated impaired fasting glycemia.
cas compared to normal glucose tolerance.
disolated impaired glucose tolerance.
econcomitant impaired fasting glycemia and impaired glucose tolerance.
doi:10.1371/journal.pone.0038224.t001
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risk score showed a significant association with both outcomes
(p=0.045 and 0.017, respectively), which was not significant when
using the simple risk score. However, even the simple, unweighted
risk score associated well with the risk for prediabetes when it was
limited to the alleles of the seven genes involved in impaired
insulin secretion (p=0.0034). Isolated IFG did not show any
significant correlation with the genetic risk (p=0.18 with the
weighted risk score).
We furthermore tested associations of the T2D-related genetic
risk with the presence of prediabetes in female/male, obese/non-
obese and insulin resistant/sensitive strata of the cohort.
The weighted risk score adjusted for age, BMI and insulin
sensitivity demonstrated an association with IGT (n=959,
p=0.008) in females, but failed to associate with IGT in males
(n=483, p=0.54). Sensitivity analysis yielded a minimal sample
size of 293 for showing the effect seen in female participants.
For the obese subjects of the cohort (n=456), a significant
association was found between the sum of weighted risk alleles and
the prevalence of IGT (p=0.008). This association was not present
in non-obese subjects (n=986, p=0.37). When investigating
insulin resistant subjects who had lower than median insulin
sensitivity indices (n=715), a significant association was found
between the weighted risk score and the prevalence of IGT
(p=0.017). This association was not present in insulin sensitive
subjects (n=714, p=0.2). These results are visualized with per-
allele odds ratios for IGT in Figure 1.
Discussion
In the present study, we asked whether the summation of risk
alleles known to be associated with diabetes is already associated
with prediabetic states. It is worthwhile to pose this question
because the genetic risk for impairing glycemia may become
relevant only when impaired glucose tolerance progresses to
diabetes, but not when normal glucose tolerance progresses to
impaired glucose tolerance. This has been shown, e.g. for SNPs in
TCF7L2 and WFS1 which become more and more relevant during
the progression of prediabetes stages towards clinically overt type 2
diabetes [14]. We decided to sum up all relevant risk genes that
associated with impaired insulin secretion, impaired insulin
sensitivity or both in our specific cohort. This approach is a
powerful way to test associations between genetic markers and
clinical outcome, because the genetic risk score can integrate
synergistic effects of individual markers.
We showed that the risk score calculated from 9 important
diabetes-related SNPs is similarly associated with a prediabetic
state of impaired glucose metabolism. This effect was independent
of well-known environmental risk factors like age, body weight and
insulin resistance. The finding suggests that genetically determined
risk for diabetes is involved in the very early transition from
normal glucose tolerance to impaired glucose tolerance.
Surprisingly BMI was negatively associated with the dichoto-
mous outcome parameter IGT in the model adjusted for insulin
sensitivity. The association of BMI with IGT was positive when
insulin sensitivity was omitted from the covariates. This suggests
that once controlling for insulin sensitivity, higher BMI becomes
protective against IGT. A possible explanation for this finding
could be a statistical dissociation of BMI into metabolically
harmful and metabolically non harmful body mass by adjustment
for insulin sensitivity. The term ‘‘metabolically benign obesity’’
describes persons with elevated body mass and normal insulin
sensitivity [26–28]. It is possible that in the non-diabetic healthy
population of the present study with a high proportion of obese
subjects (32% have BMI .30 kg/m
2), subjects with benign obesity
Figure 1. Odds ratios for IGT per risk allele in the whole cohort and in subgroups. Boxes indicate odds ratio 6 standard error; whiskers
indicate 95% confidence interval. Overall indicates whole cohort. Lean indicates BMI ,30 kg/m
2. Obese indicates BMI .=30 kg/m
2. Sensitive
indicates insulin sensitivity index .=14.3.
aadjusted for sex, age, BMI and insulin sensitivity;
b adjusted for age, BMI and insulin sensitivity;
c adjusted
for sex, age and insulin sensitivity;
d adjusted for sex, age and BMI.
doi:10.1371/journal.pone.0038224.g001
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association analysis.
It is well known that obesity and insulin sensitivity have a
modulatory effect on the detection of genetic susceptibility for
T2D [29,30]. For example, we showed that the effect of diabetes
risk SNPs on insulin secretion is only apparent in insulin resistant
individuals. Furthermore, the work of Cornelis et al suggested that
a genetic risk score had a stronger effect in predicting diabetes
among obese persons [31]. When stratifying our population in
obese and non-obese participants as well as in insulin resistant and
insulin sensitive participants, we found that the risk alleles associate
with prediabetes only in the obese and insulin resistant groups.
The effect of the genetic risk score was not present in non-obese
and insulin sensitive subjects, which suggests that leanness and
insulin sensitivity may protect from the genetic risk. Taken
together, these findings propose that not only the manifestation of
diabetes but also the manifestation of prediabetes is a result of an
interaction between environment and inherited susceptibility. This
will have to be confirmed in longitudinal studies.
Although sexual dimorphism in the effect of genetic loci on
waist-hip-ratio has already been identified [32], up to now there is
only limited data on diabetes-genes. In our study population there
were considerably less males than females. Sensitivity analysis
suggests that the lack of effect in male participants cannot be solely
explained by smaller subgroup size. In populations of European
origin, IGT is generally more prevalent among women compared
to men [33]. Although such a difference was not statistically
significant in our cohort, an ascertainment bias may have played a
role. Since about three-quarters of female participants in this study
were younger than 50 years, interaction of the investigated genetic
risk with sex hormones is a hypothetical possibility which could be
investigated in future studies. Observational data support a
connection between diabetes and sex-hormones [34]. For exam-
ple, sexual hormone binding globulin (SHBG) levels were
negatively associated with diabetes [34,35] and diabetes related
traits [36], and studies utilizing mendelian randomization with the
SHBG gene provide evidence for a causal link [37].
Restricting the investigated risk load on the genetic variants
related mainly to insulin secretion (7 out of 9 SNPs) did not
abolish, but rather strengthen the association with prediabetes.
One may therefore speculate that the genetic risk for prediabetes is
mediated mainly through the genetic variation affecting insulin
secretion.
From the categories of increased risk for diabetes, IGT was most
consistently associated with genetic risk. Testing isolated IFG or
IGT groups deleted some of the associations. This may be caused
by the fact that IGT has stronger associations with the risk genes
tested here than IFG, or simply by low statistical power when
testing the smaller isolated IGT and IFG groups separately.
This study is limited by several factors. Out of approximately 40
known diabetes-related variants only 9 were tested. The fact that
our cohort is not population-based, the relatively large prevalence
of prediabetic conditions among participants (28%) and the female
predominance could probably have led to some recruiting bias.
Yet our study provides a proof of concept that IGT can be
determined by a genetic risk score. It was demonstrated that the
weighted sum of alleles that associate with an increased risk for
manifest diabetes also predicts an increased risk for IGT. This
effect was mainly restricted to obese and insulin resistant
individuals and is not present in lean and insulin sensitive subjects,
suggesting a modulating role of these factors on the genetic risk. In
the future, intensive lifestyle intervention to pre-empt and treat
obesity could be preferentially targeted on those with higher
genetic risk to yield greater efficiencies in preventing diabetes.
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